2024 年至 2031 年干细胞检测市场（按产品、检测方法、应用和地区划分）

2024 年至 2031 年干细胞检测市场评估

对再生和个人化医疗的日益增长的需求是推动干细胞检测市场发展的因素之一。根据 Verified Market Research 分析师的预测，干细胞检测市场规模预计将在预测期内达到 78.1 亿美元，到 2023 年将超过约 19.3 亿美元。

干细胞研究在毒理学和药物发现的应用日益广泛，也推动了干细胞检测市场的发展。 2024年至2031年的复合年增长率为19.07%。

干细胞检测市场定义/概述

干细胞检测是评估干细胞特性和行为的实验技术。在受控条件下对干细胞进行测试，以确定其自我更新、分化为多种细胞类型以及增殖的能力。干细胞检测在生物医学研究和再生医学中发挥重要作用，其应用范围包括药物发现和开发到毒理学筛选和疾病建模。

此外，干细胞检测可透过确定潜在治疗剂对干细胞分化和功能的影响来帮助药物开发。这些检测方法也用于研究发育过程、筛检药物毒性以及研究癌症和神经系统疾病等疾病的病因。

哪些方面影响干细胞检测市场的成长？

主要的驱动力是干细胞研究的不断发展以及干细胞分离、培养和分化方面的突破性研发。这些技术进步提高了干细胞检测的效率和有效性，使其在药物研发、再生医学和基础研究等各种应用领域更具吸引力。 3D 细胞培养技术、高通量筛选方法等创新以及成像和分析工具的进步都在推动市场扩张。

人们对再生医学的兴趣日益浓厚，以及干细胞治疗心血管、神经和糖尿病等各种疾病的潜力，推动了对干细胞检测的需求。政府、企业和学术机构正在迅速投资干细胞研究以探索治疗应用，从而产生了对评估干细胞疗法的有效性和安全性的测试的需求。

此外，全球慢性病和遗传疾病的增加使得开发新药物和治疗方法成为必要。干细胞是产生此类疗法的潜在选择，推动了疾病建模、药物开发和个人化医疗对干细胞检测的需求。随着学术界和製药公司致力于瞭解疾病原因并测试新的治疗方法，对干细胞检测的需求也日益增长。

干细胞检测中的技术问题会影响市场成长吗？

儘管干细胞研究取得了进展，但如何有效将干细胞分化为所需的细胞类型、如何保持干细胞培养物的稳定性和纯度以及如何使检测方法在多个实验室中可重复，仍是一个难题。这些课题影响了干细胞检测的可靠性和有效性，使得程序难以标准化和获得一致的结果，并限制了市场扩张。

开发和实施干细胞检测需要在专门的设备、试剂和专业知识上进行大量投资。此类检测的高成本对于资源有限的学术机构和中小企业来说是一个障碍。此外，干细胞研究具有长期性，且干细胞药物的商业潜力存在不确定性，投资风险较大。这些财务障碍阻碍了干细胞检测业务的成长并限制了其扩张。

目录

第 1 章全球干细胞检测市场：简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章 干细胞检测的全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第5章 全球干细胞检测市场（依产品划分）

• 概述
• 试剂和试剂盒
• 装置

第6章全球干细胞检测市场（依应用）

• 概述
• 再生医学与治疗
• 临床研究
• 药物发现与开发

第7章 全球干细胞检测市场（依检测方式）

• 概述
• 细胞辨识试验
• 活力或细胞毒性检测
• 细胞凋亡检测
• 分离纯化测定
• 其他

第8章 全球干细胞检测市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 9 章干细胞检测全球市场：竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第10章 公司简介

• Thermo Fisher Scientific
• Perkinelmer
• Stemcell Technologies
• Merck
• Bio-Rad Laboratories
• Agilent Technologies

第11章 附录

• 关联调查

Stem Cell Assay Market Valuation - 2024-2031

The growing need for regenerative therapies and personalized medicine is one factor propelling the stem cell assay market. According to the analyst from Verified Market Research, the stem cell assay market is estimated to reach a valuation of USD 7.81 Billion over the forecast period, surpassing around USD 1.93 Billion valued in 2023.

The growing use of stem cell research in toxicology and drug discovery is another factor propelling the market for stem cell assays. It enables the market to grow at a CAGR of 19.07% from 2024 to 2031.

Stem Cell Assay Market: Definition/Overview

A stem cell assay is a laboratory technique for assessing the properties and behavior of stem cells. It entails testing stem cells in controlled conditions to determine their ability to self-renew, differentiate into diverse cell types, and proliferate. Stem cell assays play an important role in biomedical research and regenerative medicine, with applications spanning from drug discovery and development to toxicological screening and disease modelling.

Furthermore, stem cell assays aid in drug development by determining the impact of prospective therapeutic drugs on stem cell differentiation and function. Also, these assays are utilized to research developmental processes, screen for pharmacological toxicities, and investigate disease causes such as cancer and neurological illnesses.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Aspects Influencing the Growth of the Stem Cell Assay Market?

Continuous advancements in stem cell research, as well as the development of breakthrough methods for stem cell isolation, culturing, and differentiation, are key drivers. These technical advancements increase the efficiency and effectiveness of stem cell assays, making them more appealing for a variety of applications such as drug development, regenerative medicine, and fundamental research. Innovations such as 3D cell culture techniques, high-throughput screening methodologies, and advances in imaging and analytical tools all help to drive market expansion.

The growing interest in regenerative medicine, as well as the potential of stem cells to treat a variety of ailments such as cardiovascular disease, neurological disorders, and diabetes, is driving demand for stem cell assays. Governments, business companies, and academic institutions are rapidly investing in stem cell research to investigate therapeutic applications, creating a demand for tests used to assess the efficiency and safety of stem cell-based therapies.

Furthermore, the increasing global prevalence of chronic diseases and genetic disorders needs the development of new medicines and therapies. Stem cells represent a possible option for generating such treatments, increasing the demand for stem cell assays in disease modelling, drug development, and personalized medicine. The need for stem cell assays is increasing as academics and pharmaceutical companies work to better understand disease causes and test new treatments.

Will Technical Issues of Stem Cell Assay Impact the Growth of Market?

Despite advances in stem cell research, significant technical and scientific challenges remain, such as efficiently differentiating stem cells into desired cell types, maintaining the stability and purity of stem cell cultures, and ensuring assay reproducibility across multiple laboratories. These challenges have an impact on the reliability and effectiveness of stem cell assays, making it difficult to standardize techniques and generate consistent results, hence limiting market expansion.

Creating and running stem cell assays necessitates significant expenditure on specialised equipment, reagents, and expert personnel. The high costs of these assays represent a hurdle for academic institutions and small-to-medium businesses with limited resources. Furthermore, the long-term nature of stem cell research, as well as uncertainties about the commercial feasibility of stem cell-based medicines, represent major investment risks. These financial obstacles stymie the growth of the stem cell assay business, limiting its expansion.

Category-wise Acumens

What dynamics Contribute to the Dominance of Reagents and Kits Products?

According to VMR analyst, the reagents and kits segment is estimated to dominate the stem cell assay market during the forecast period. Reagents and kits are consumables used extensively in stem cell tests such as cell proliferation, differentiation, viability, and toxicity. Reagents and kits are in high demand due to their importance in daily laboratory operations and their recurrent nature. This need is being driven by continuous research and development efforts in both academic and commercial contexts, where stem cell assays are critical for drug discovery, therapeutic development, and basic research.

Reagents and kits are designed to meet a wide range of needs, from basic research to specific therapeutic areas. This versatility is strengthened by the ability to tailor kits to specific types of stem cells or tests. Such customization and application flexibility ensure that reagents and kits continue to be in high demand across a wide range of research areas and medicinal development projects, contributing to their market domination.

Furthermore, compared to instruments, which require significant initial capital investment and maintenance expenditures, reagents and kits are less expensive and more accessible to a larger range of customers, including small research labs and entrepreneurs. This decreased cost barrier promotes widespread adoption and continuing purchasing of reagents and kits, resulting in a bigger market share.

How do the Cytotoxicity Assays Influence the Growth Trajectory of the Market?

The viability or cytotoxicity assays segment is estimated to hold the largest share of the stem cell assay market during the forecast period. Viability or cytotoxicity assays are critical for determining the effects of medicines on cell health and survival, making them indispensable during the early stages of drug discovery and development. These tests assist evaluate the therapeutic index of drug candidates by analyzing their toxic effects on cells, making them critical in discovering possible treatments with the fewest cytotoxic effects.

Additionally, the expanding pharmaceutical and biotechnology companies' investment in new drug development fueling demand for these assays.

Furthermore, viability or cytotoxicity assays are versatile and can be used in a variety of research domains, including toxicology, cancer, and regenerative medicine. They are employed not just in stem cell research, but also in experiments with primary cells, cancer cells, and other cell lines. This broad applicability across several scientific and clinical sectors leads to their large market share.

Country/Region-wise Acumens

What are the Key Drivers Influencing the North American Stem Cell Assay Market?

North America is estimated to dominate the stem cell assay market during the forecast period. North America, particularly the United States, has a strong research and development infrastructure, with world-class universities, research institutions, and biotechnology and pharmaceutical corporations. This environment encourages innovation and enables ground-breaking research in stem cell technology and applications.

The presence of excellent research facilities and a highly skilled workforce facilitates the development, validation, and commercialization of stem cell assays, contributing considerably to the region's market leadership.

Furthermore, compared to other regions, North America, particularly the United States, offers a more favourable regulatory framework for stem cell research and therapeutic development. Regulatory authorities, such as the United States Food and Drug Administration (FDA), have created criteria and routes for the research and approval of stem cell-based medicines. This regulatory environment promotes innovation while maintaining safety and efficacy, making the region appealing to enterprises and researchers involved in the stem cell assay market.

What Factors Contribute to Surging Demand for Stem Cell Assays in the Asia Pacific?

Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Many Asian Pacific countries have established major programs and financing schemes to encourage life science research and development, such as stem cell research and regenerative medicine. Governments in Japan, South Korea, China, and Australia are aggressively pushing stem cell research by providing direct money, establishing research centres, and forming collaborations with the commercial sector. These efforts aim to establish these countries as worldwide leaders in biotechnology and healthcare innovation, ultimately boosting the growth of the stem cell assay market.

Furthermore, Asia Pacific is experiencing an increase in the prevalence of chronic diseases such as diabetes, cardiovascular disease, and neurological disorders, owing to an ageing population. This demographic transition raises the demand for novel cures and medical treatments, particularly those based on stem cell research. Stem cell assays are crucial in the development of these therapies because they facilitate drug discovery, toxicity testing, and disease mechanism comprehension, hence promoting regional market growth.

Competitive Landscape

The competitive landscape of the stem cell assay market is defined by a dynamic interaction of many elements, such as technological breakthroughs, R&D initiatives, regulatory frameworks, and strategic alliances. Furthermore, the presence of severe regulatory requirements for stem cell research and therapeutic development emphasizes the necessity of compliance and quality assurance, which increases market rivalry.

Some of the prominent players operating in the stem cell assay market include:

Thermo Fisher Scientific

Merck KGaA

Danaher

Becton, Dickinson and Company

Bio-Rad Laboratories

PerkinElmer

Agilent Technologies

Promega Corporation

Cell Biolabs

Miltenyi Biotec

STEMCELL Technologies

Bio-Techne Corporation

FUJIFILM Holdings Corporation

Sartorius Stedim Biotech

GE Healthcare

Roche Diagnostics

Latest Developments:

In February 2024, Thermo Fisher, a prominent market player, introduced an innovative serum-free stem cell culture medium that claims to promote stem cell multiplication and differentiation. This could be a huge advancement for companies developing stem cell medicines.

In February 2024, Danaher, another significant competitor, purchased a company that specializes in cell analysis technology. Danaher's position in the stem cell assay industry could be strengthened by this acquisition, which will provide improved stem cell characterization tools.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL STEM CELL ASSAY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL STEM CELL ASSAY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL STEM CELL ASSAY MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Reagents and Kits
• 5.3 Instruments

6 GLOBAL STEM CELL ASSAY MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Regenerative Medicine and Therapy
• 6.3 Clinical Research
• 6.4 Drug Discovery and Development

7 GLOBAL STEM CELL ASSAY MARKET, BY ASSAY

• 7.1 Overview
• 7.2 Cell Identification Assays
• 7.3 Viability or Cytotoxicity Assays
• 7.4 Apoptosis Assays
• 7.5 Isolation & Purification Assays
• 7.6 Others

8 GLOBAL STEM CELL ASSAY MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL STEM CELL ASSAY MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Thermo Fisher Scientific
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Perkinelmer
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Stemcell Technologies
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Merck
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Bio-Rad Laboratories
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Agilent Technologies
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments

11 Appendix

• 11.1 Related Research